GlassScriptPhysician profile
Lisa D Mullally
NPI 1861462012
$8,503.56
in general payments reported to CMS, 2019-2025
66 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,457 · 2020: $1,019 · 2021: $1,609 · 2022: $964 · 2023: $1,102 · 2024: $1,171 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,409 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,408.56 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,345.43 | 2021-2025 | |
| Novo Nordisk INC | $1,245.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $774.89 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $463.85 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $344.96 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $303.45 | 2021-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $287.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $224.81 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $203.95 | 2019-2022 | |
| Glaxosmithkline, LLC. | $203.54 | 2019-2025 | Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $198.84 | 2019-2024 | Linzess |
| Otsuka America Pharmaceutical, INC. | $197.46 | 2022-2024 | Rexulti |
| Allergan, INC. | $191.15 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $156.05 | 2020-2021 | |
| Esperion Therapeutics, INC. | $147.35 | 2020-2025 | Nexletol |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Mullally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.